We represented Sun Pharma in the acquisition of the minority interest in Taro
23 January 2024
It was our pleasure to represent Sun Pharmaceutical Industries Limited (SUN.NS), in its acquisition of the minority interest in Taro Pharmaceutical Industries (TARO.N). The transaction represents a valuation of Taro of approximately $ 1.65 billion, and the total amount of the transaction is expected to be approximately $ 350 million.
This transaction was led by partners Nir Dash, Niv Sivan, and Nathan Wiesenberg and associate David Azimov, as well as specialist from different teams in the firm.